Exhibit 99.1 QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― February 11, 2026 SAN DIEGO, CA — QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for ...

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results [Accessibility Statement] Skip Navigation Delivered 6% Labs and 9% TRIAGEâ"¢ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today an ...

Core Insights - QuidelOrtho has received a Gold Stevie Award in Customer Service Success and a Bronze Stevie Award in AI & Tech Focused Digital Transformation Team of the Year, highlighting its commitment to customer experience [1][2] - The Excellence Services Label, reflecting adherence to ISO 23592, confirms QuidelOrtho's dedication to customer-centric systems and high-quality service delivery [2][4][8] Awards and Recognition - The Stevie Awards are recognized globally for excellence in customer service, business development, and sales, with QuidelOrtho being honored in two categories [3] - The Gold and Bronze Stevie Awards signify QuidelOrtho's effective customer-first approach and innovative service improvements [2] Customer Experience Commitment - QuidelOrthoCQ is a company-wide initiative aimed at embodying customer values and enhancing the overall customer experience [5] - The Excellence Services Label provides third-party validation of QuidelOrtho's commitment to delivering consistent and high-quality service experiences [4][8] Organizational Overview - QuidelOrtho Corporation specializes in diagnostic solutions across various fields, including clinical chemistry and molecular testing, aiming to improve patient outcomes [7] - The company collaborates with healthcare providers to advance diagnostics and facilitate informed decision-making [7]

Core Insights - QuidelOrtho Corporation emphasizes the importance of consistent donor engagement to address pressures on the blood supply [1][2] - The podcast discusses how evolving clinical practices, climate disruptions, and persistent demand shape the modern blood supply [2] Industry Context - Everyday emergencies and climate-driven events create unpredictable demand for blood products, impacting supply [5] - The growth of prehospital low-titer whole blood programs increases the consumption of O-type units, necessitating targeted donor recruitment and precise inventory management [5] - Automation through standardized, high-throughput immunohematology platforms enhances safety and operational continuity during demand surges [5] - Every blood type is crucial for supporting transfusion needs and the diagnostic reagents necessary for safe transfusions [5] Company Overview - QuidelOrtho Corporation is a leading global provider of diagnostic solutions, focusing on advancing fast, accurate, and reliable results to improve patient outcomes [4] - The company collaborates with healthcare providers to enhance diagnostics that connect insights with solutions, facilitating informed decisions and better care [4]

Core Viewpoint - QuidelOrtho Corporation will report its financial results for Q4 and full year 2025 on February 11, 2026, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call starting at 2:00 p.m. PT / 5:00 p.m. ET [2] - Interested parties can access the call via the Company's website or by phone using specific dial-in numbers [2] Conference Call Replay - A replay of the conference call will be available shortly after the event on the Company's website [3] Company Overview - QuidelOrtho Corporation is a leading global provider of diagnostic solutions, focusing on advancing fast, accurate, and reliable results to improve patient outcomes [4] - The company has expertise in clinical chemistry, immunoassay, immunohematology, and molecular testing [4]

Core Insights - QuidelOrtho Corporation is at the forefront of in vitro diagnostics, focusing on innovative solutions that enhance patient care [1][7] - The latest podcast episode discusses transformative diagnostic technologies that are reshaping patient management and outcomes [2][3] Diagnostic Innovations - High-sensitivity troponin testing is enabling faster diagnosis and treatment for cardiac patients, improving care efficiency [5] - Non-invasive assays are being developed to enhance gastrointestinal health, reducing the need for invasive procedures [5] - Rapid combination tests are assisting clinicians in effectively managing respiratory surges, streamlining patient care [5] - Advances in molecular diagnostics, informatics, and artificial intelligence are facilitating more personalized and smarter healthcare solutions [5] Research and Development - QuidelOrtho's R&D strategies are focused on addressing global healthcare challenges through innovative diagnostic solutions [5][7] - Collaboration and cutting-edge research are key drivers behind the diagnostic breakthroughs that empower clinicians worldwide [3]

Company Overview - QuidelOrtho Corporation is a leading provider of diagnostic testing solutions with a global footprint and a diversified product portfolio [5] - The company focuses on innovation in diagnostic technologies and expanding access to rapid and accurate testing for both professional and consumer markets [6] - QuidelOrtho generates revenue through direct sales and distribution of diagnostic equipment and consumables to various healthcare providers and laboratories [9] Financial Performance - As of September 30, QuidelOrtho reported a revenue of $2.7 billion and a net income of -$1.2 billion [4] - The company's shares were priced at $27.76, reflecting a 26% decline over the past year, underperforming the S&P 500, which increased by 13% during the same period [3] - The latest quarter showed signs of stabilization in core business, with non-respiratory revenue and lab revenue both growing by 5% [10] Investment Insights - Newtyn Management increased its stake in QuidelOrtho by purchasing 994,332 shares for approximately $30.4 million, raising its total position to 2.7 million shares valued at $79.5 million [2][3] - QuidelOrtho's adjusted EBITDA margin expanded to 25%, up 180 basis points from the previous year, indicating improved cost efficiencies [10] - The company has seen nearly a 90% decline in share value since 2020, but recent operational improvements may suggest a more durable growth trajectory [10][11]

Group 1 - The stock reaction after the third quarter was surprising, with a steep sell-off followed by a notable bounce back [2] - There were insider purchases observed, which were positively received by the market [2] - Feedback from investors post-quarter indicated some pushback regarding the company's performance [2]

Financial Data and Key Metrics Changes - The company reported total revenue growth of 5% for the quarter, excluding COVID and donor screening revenue, indicating solid performance above expectations [15][10] - Adjusted Free Cash Flow guidance for the full year is expected to be 25%-30% of Adjusted EBITDA, with a strong Q4 anticipated due to delayed cash receipts from Q3 [10][11] - The leverage ratio at the end of Q3 was 4.4, which is considered too high, with a target range of 2.5-3.5 times expected by early 2027 [72][73] Business Line Data and Key Metrics Changes - The Labs business grew by 4% in Q3, with immunohematology growing at 5% and Triage at 7%, indicating a stable mid-single digit growth trajectory [15][16] - The immunohematology business holds the number one market position globally, achieving 5% growth in Q3, although Q4 growth is expected to be lower due to shipment timing [34][35] - The Point-of-Care business, particularly Triage, is expected to grow at a high single-digit rate, driven by improved cost management and market competitiveness [43][44] Market Data and Key Metrics Changes - The Chinese market is expected to grow at a mid-single digit rate for the full year 2025, with the company feeling optimistic about opportunities despite previous reimbursement issues [29][33] - The company has been less affected by Chinese government actions aimed at cost reduction compared to competitors, primarily due to its focus on routine chemistry [28][31] Company Strategy and Development Direction - The company aims to increase its integrated analyzer base from 30% to around 50%, which is expected to enhance margins by 10-20 basis points annually [22][23] - The exit from the U.S. donor screening market is projected to reduce revenue headwinds from 2-3 points this year to about 1 point next year, with margin accretion expected post-exit [40][41] - The company is focused on continuous improvement in staffing rather than large-scale cuts, aiming for a more stable operational environment [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single digit growth in the Labs and immunohematology segments, with a stable revenue base [68] - The approval of the high-sensitivity troponin assay is seen as a confidence booster for maintaining growth in the Labs business [26] - The company anticipates that the LEX acquisition will likely be dilutive in 2026 but expects to reverse this trend by 2027 [70][69] Other Important Information - The company has achieved $140 million in cost savings since mid-2024, primarily through staffing reductions and indirect procurement initiatives [65] - The company is monitoring the impact of COVID revenue decline, which is expected to decrease by about $100 million year-over-year [44] Q&A Session Summary Question: Feedback from investors post-Q3 earnings - Management noted that the stock reaction was perplexing, attributed to high short interest, put option exposure, tax loss selling, and cash flow timing issues related to ERP conversions [6][10] Question: Cash flow guidance and visibility - The company is tracking towards its cash flow guidance of 25%-30% of Adjusted EBITDA, with expectations for a strong Q4 due to cash collection delays [10][12] Question: Growth drivers in the Labs business - The Labs business is expected to maintain a mid-single digit growth trajectory, supported by consistent win rates and integrated analyzer strategy [16][18] Question: Competitive dynamics in China - The company has been less impacted by reimbursement actions in China and expects mid-single digit growth in the market moving forward [28][29] Question: Margin improvement initiatives - The company is targeting 100-200 basis points of margin improvement in 2026, contingent on continued mid-single digit growth in the base business [66][70]

Financial Data and Key Metrics Changes - The company is tracking towards an Adjusted Free Cash Flow guidance of 25%-30% of Adjusted EBITDA for the full year, despite a hiccup in Q3 due to system conversion delays [10][11] - The long-term target for cash flow is to reach 50% of Adjusted EBITDA by 2027, with expected progress in 2026 [11] - Total revenue growth, excluding COVID and donor screening revenue, was reported at 5% for the quarter and year-to-date [15][16] Business Line Data and Key Metrics Changes - The Labs business grew at 4% in constant currency, while Immunohematology and Triage grew at 5% and 7% respectively, indicating solid performance across the base business [15][16] - The immunoassay to integrated analyzer ratio has improved from 25% to 30%, with a target of reaching 50% in the future, which is expected to enhance margins [22][23] Market Data and Key Metrics Changes - The Chinese market is expected to grow at a mid-single digit rate for the full year 2025, with the company feeling optimistic about opportunities despite previous reimbursement issues [29][32] - The immunohematology business holds the number one market position globally, with a growth rate of 5% in Q3, although Q4 growth may be lower due to shipment timing [33] Company Strategy and Development Direction - The company is focusing on optimizing its portfolio by exiting the U.S. donor screening market, which is expected to improve margins once fully wound down [39][40] - The strategy includes enhancing the integrated analyzer base to drive higher-margin immunoassay revenue, with a long runway for growth in this area [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single digit growth in the Labs and Immunohematology segments, with expectations for stable performance in the face of market challenges [15][16][29] - The company anticipates a good Q4 and is optimistic about the overall market dynamics, particularly in China and the point-of-care segment [29][41] Other Important Information - The company has achieved $140 million in cost savings since mid-2024, primarily through staffing reductions and indirect procurement initiatives [62] - The leverage ratio at the end of Q3 was reported at 4.4, with a target to reduce it to 2.5-3.5 times by early 2027 [70][71] Q&A Session Summary Question: Feedback from investors post-Q3 earnings call - Management noted that the stock reaction was perplexing, attributing it to high short interest, put option exposure, and cash flow timing issues related to ERP conversions [7][10] Question: Cash flow guidance and visibility - The company confirmed that cash flow guidance remains unchanged, with expectations for a strong Q4 as cash receipts from Q3 are collected [10][12] Question: Growth drivers in the Labs business - The Labs business is expected to maintain a mid-single digit growth trajectory, supported by consistent win rates and a stable contract structure [16][18] Question: Competitive dynamics in China - Management indicated that the company has been less affected by Chinese government actions compared to competitors, expecting mid-single digit growth in the Chinese market [28][32] Question: Margin improvement initiatives - The company is targeting 100-200 basis points of margin improvement in 2026, contingent on continued mid-single digit growth in the base business [62][65] Question: Future of the LEX acquisition - The company expects to complete the acquisition of LEX following FDA approval, with a limited commercial rollout anticipated in the first half of 2026 [51][56]